Show simple item record

A phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutation

dc.contributor.authorLindsay, Colin Ren
dc.contributor.authorVeluswamy, R.en
dc.contributor.authorCastro, G.en
dc.contributor.authorTan, D. S. W.en
dc.contributor.authorCaparica, R.en
dc.contributor.authorGlaser, S.en
dc.contributor.authorMalhotra, S.en
dc.contributor.authorBoran, A.en
dc.contributor.authorFelip, E.en
dc.date.accessioned2023-10-25T08:48:39Z
dc.date.available2023-10-25T08:48:39Z
dc.date.issued2023en
dc.identifier.citationLindsay CR, Veluswamy R, Castro G, Tan DSW, Caparica R, Glaser S, et al. A phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutation. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005506.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS9158en
dc.identifier.urihttp://hdl.handle.net/10541/626666
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9158en
dc.titleA phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutationen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie Hospital NHS Foundation Trust, Manchesteren
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record